Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Recombinant Antibody. This antibody reacts to human Akt1. This antibody may also react to bovine, mouse or rat Akt1, as predicted by immunogen homology. Applications: WB, IHC. Source: Rabbit. Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. Akt, also referred to as PKB or Rac, plays a critical role in controlling survival and apoptosis. This protein kinase is activated at 2 phosphorylation sites Thr308 and Ser473. Akt promotes cell survival by inhibiting apoptosis through phosphorylation and inactivation of several targets, including Bad, forkhead transcription factors, c-Raf and caspase-9. In addition to its role in survival and glycogen synthesis, Akt is involved in cell cycle regulation. Akt also plays a critical role in cell growth by directly phosphorylating mTOR in a rapamycin-sensitive complex containing raptor. Mutation of the glutamic acid at residue 17 to lysine (E17K) of Akt was initially identified in human breast, colorectal and ovarian cancers. This conserved glutamic acid residue is located at the lipid-binding pocket of the Akt plextrin homology domain. The E17K mutation increases the affinity between Akt and phospholipids at the plasma membrane, leading to increased Akt recruitment, super-activation of the Akt pathway, cellular transformation and tumor formation. Additional studies detect the presence of the Akt (E17K) mutation in multiple cancers, including lung cancer, prostate cancer, endometrial carcinoma and several melanomas.
Alerte
Veuillez saisir les champs obligatoires! |